Effects of PCSK9 inhibitors on oxidized low-density lipoprotein (ox-LDL) and lipid profile in patients with cardiovascular disease
Yu Hailong
Deng Zhihui
Lin Jingye
Abstract：Objective To study the effect of PCSK9 inhibitor on oxidized low density lipoprotein (ox-LDL) and blood lipid profile in patients with cardiovascular diseases.Methods Clinical data were retrospectively collected from 274 patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) diagnosed in our hospital.The patients were divided into an evolocumab group (117 patients) and a statin monotherapy group (157 patients) according to the use of evolocumab (a PCSK9 inhibitor) or not after percutaneous coronary intervention (PCI).The levels of ox-LDL,total cholesterol (TC),triglycerides (TG),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C),and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups on admission and after 2 weeks of treatment.Results After 2 weeks of treatment,the levels of ox-LDL,TC,and TG were significantly lower in the evolocumab and statin monotherapy groups than before treatment (P＜0.05).The reduction of ox-LDL,TC and TG levels was more significant in the evolocumab group than in the statin monotherapy group (P＜0.05).Conclusion PCSK9 inhibitors can reduce the levels of ox-LDL and lipid parameters in very high-risk ASCVD patients in a short period of time.
Keywords：PCSK9 inhibitoroxidized low-density lipoproteinLipid profileVery high-risk ASCVD
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1487-1490 )